1. Home
  2. PKOH vs CLLS Comparison

PKOH vs CLLS Comparison

Compare PKOH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park-Ohio Holdings Corp.

PKOH

Park-Ohio Holdings Corp.

HOLD

Current Price

$21.21

Market Cap

283.3M

Sector

Industrials

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.98

Market Cap

299.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PKOH
CLLS
Founded
1907
1999
Country
United States
France
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.3M
299.0M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
PKOH
CLLS
Price
$21.21
$4.98
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
32.9K
124.5K
Earning Date
11-05-2025
11-07-2025
Dividend Yield
2.42%
N/A
EPS Growth
30.26
N/A
EPS
1.68
N/A
Revenue
$1,592,500,000.00
$82,551,000.00
Revenue This Year
$0.23
N/A
Revenue Next Year
$3.07
$58.00
P/E Ratio
$9.94
N/A
Revenue Growth
N/A
129.04
52 Week Low
$15.52
$1.10
52 Week High
$33.19
$5.48

Technical Indicators

Market Signals
Indicator
PKOH
CLLS
Relative Strength Index (RSI) 60.73 69.02
Support Level $18.69 $4.90
Resistance Level $20.50 $5.35
Average True Range (ATR) 0.74 0.28
MACD 0.19 0.14
Stochastic Oscillator 98.20 85.56

Price Performance

Historical Comparison
PKOH
CLLS

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: